Ranozex 500 mg (Tablet (Extended Release))
Unit Price: ৳ 16.00 (3 x 10: ৳ 480.00)
Strip Price: ৳ 160.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Ranolazine |
| Company | Sun pharmaceutical bangladesh ltd |
Title
Ranozex Medicine
Category
- Cardiovascular Medicine
- Anti-anginal
- Anti-ischaemic
Description
Ranozex is indicated for the treatment of chronic angina. It may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers.
Color Options
- White
Dimensions
Standard tablet size
Dosage
Initiate at 500 mg twice daily and increase to 1000 mg twice daily, if needed, based on clinical symptoms
Administration
Swallow whole; do not crush, break, or chew. Take with or without meals.
Interaction
- CYP 3A Inhibitors: Do not use with strong CYP 3A inhibitors. Limit maximum dose to 500 mg twice daily with moderate CYP 3A inhibitors
- CYP 3A Inducers: Do not use with inducers
- P-gp Inhibitors: May need to lower the dose based on clinical response
- Drugs Transported by P-gp or Metabolized by CYP2D6: May need reduced doses when used with Ranozex
Contraindications
- Pre-existing QT prolongation
- Hepatic impairment
- Taking QT prolonging drugs
- Taking potent and moderately potent CYP3A inhibitors
Side Effects
- Bradycardia
- Palpitations
- Tinnitus
- Vertigo
- Abdominal pain
- Dry mouth
- Vomiting
- Peripheral edema
- Dyspnea
- Hypotension
- Orthostatic hypotension
Pregnancy & Lactation
- Pregnancy Category: C
- Effect on Fetus: Unknown
- Effect on Nursing Infants: Serious adverse reactions possible
Mode of Action
- Effect: Anti-ischemic and anti-anginal effects
- Mechanism: Inhibition of cardiac late sodium current (I_Na), QT prolongation effect by inhibition of I_Kr
Precautions & Warnings
Blocks QTc and prolongs the QTc interval, caution with co-administration of P-gp inhibitors
Overdose Effects
- Dizziness
- Nausea
- Vomiting
- Diplopia
- Paresthesia
- Confusion
- Syncope
Absorption
- Cmax: 2-5 hours
- Half-life: 6-22 hours
- Distribution: Approximately 62% bound to human plasma proteins
- Metabolism and Excretion: Metabolized mainly by CYP3A and to a lesser extent by CYP2D6, excreted primarily in urine and feces
Therapeutic Class
Other Anti-anginal & Anti-ischaemic drugs
Storage Conditions
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.